Mantle Cell Lymphoma: Clinicopathologic Features and Treatments

Mantle Cell Lymphoma: Clinicopathologic Features and Treatments

Drs. Baidas, Cheson, Kauh, and Ozdemirli present a thorough and balanced review of mantle cell lymphoma (MCL) and the various current treatment options. MCL has been recognized as a distinct pathologic entity for over a decade. It represents 6% to 9% of all non- Hodgkin's lymphoma cases, and the diagnosis is based on a combination of morphologic, immunophenotypic, and cytogenetic criteria as discussed in the article. The hallmark of MCL is t(11;14)(q13;q32), a translocation that juxtaposes the Bcl-1 gene on chromosome 11 and immunoglobulin (Ig)H promoter on chromosome 14, leading to overexpression of cyclin D1. Although it had been considered an indolent lymphoma for many years, MCL has a poor prognosis with short remissions and a median survival of 3 to 4 years.[1,2] Conventional Chemotherapy
As discussed in the article, numerous chemotherapy regimens have been reported in the treatment of MCL, and optimal therapy is yet to be established. The role of anthracyclines in the treatment of this disease is still unclear, as some studies[3-6] have demonstrated improved overall survival and others[7-11] have failed to demonstrate such benefit. In a retrospective study in 68 MCL patients treated at the University of Nebraska Medical Center, 79% received an anthracycline-based regimen and 21% received a non-anthracycline- based regimen. Survival among patients treated with anthracycline- based regimens was no better than that in the other group.[12] More recently, more intensive regimens have been evaluated for the treatment of MCL, such as the hyper- CVAD regimen (hyperfractionated cyclophosphamide [Cytoxan, Neosar], vincristine, doxorubicin [Adriamycin], dexamethasone).[13] As pointed out in the review, when combined with rituximab (Rituxan), this regimen produces promising results; further study of the combinaton in a cooperative group setting is planned. The need for the addition of highdose chemotherapy and stem cell transplantation in patients in first complete response who are receiving hyperCVAD is still unknown and also needs further evaluation. High-Dose Chemotherapy Followed by Stem Cell Transplant
Because conventional chemotherapy is not thought to be curative in most patients with MCL, high-dose chemotherapy followed by stem cell transplant has been evaluated in an effort to improve survival rates. No prospective randomized study comparing conventional therapy with highdose chemotherapy followed by stem cell transplant has yet been published. However, several phase II trials of stem cell transplant in MCL patients have been published. Most of these studies demonstrated that patients are more likely to benefit from this approach if the transplant is performed earlier in the course of the disease (ie, first complete response).[14] Improvements in this approach include better induction chemotherapy, such as rituximab/hyperCVAD, and the addition of other agents to modify the transplant regimen, such as rituximab for in vivo purging[15] or radioimmunotherapy with tositumomab/ iodine-131 tositumomab (Bexxar) or ibritumomab tiuxetan (Zevalin).[16-18] However, as the authors point out, autologous stem cell transplant may only improve the response rate and time to treatment failure without achieving cure. An alternative to this approach, which was not discussed extensively in the article, is the use of high-dose chemoradiotherapy and an allogeneic stem cell transplant. Such a protocol was evaluated in a selected population of young MCL patients.[ 19,20] At the University of Nebraska Medical Center, we performed transplants in 20 MCL patients using a fully myeloablative regimen with a related allogeneic donor; 45% of patients are alive and disease-free between 1 and 9 years posttransplant (Figure 1). However, allogeneic stem cell transplant has a limited role in MCL, as most patients with this disease are over 60 years old. The toxicity of allogeneic transplant could be reduced by using nonmyeloablative regimens. Immunotherapy
When used as a single agent in clinical trials, rituximab has produced response rates of 20% to 40% in MCL patients. Phase II trials of rituximab plus combination chemotherapy have achieved promising results in MCL patients, with overall response rates ranging from 92% to 100% and complete response rates, from 48% to 98%. The German Low-Grade Lymphoma Study Group (GLSG) has conducted two randomized trials comparing standard chemotherapy with chemotherapy plus rituximab in patients with MCL and follicular lymphoma. In the first study, patients were randomized to FCM alone (fludarabine [Fludara], cyclophosphamide, mitoxantrone [Novantrone]) or FCM with rituximab (R+FCM). Patients who achieved a complete or partial response underwent a second randomization to either maintenance therapy with rituximab or observation alone. The overall response rate to R+FCM was 65% (35% complete response) compared with a 33% overall response rate (0% complete response) to FCM alone.[21] In the second phase III randomized study of R-CHOP (rituximab plus cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone) vs CHOP, the subset of evaluable MCL patients who received R-CHOP achieved higher overall response rates than did those treated with CHOP alone (95% vs 76%).[21] An additional therapy for MCL currently being evaluated is the idiotype vaccine as an adjuvant to immunotherapy. In these studies, the patient's lymphoma is biopsied and a patient-specific vaccine is manufactured. The EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) plus idiotype vaccine and the CHOP plus idiotype vaccine are examples of two such regimens being tested in clinical trials.[22,23] Novel Agents
Because standard therapies are not curative in MCL and many patients are not candidates for transplant, novel agents are being evaluated to enhance the efficacy of MCL treatment. Examples of ongoing trials not discussed in the article include studies of novel agents such as bortezomib (PS-341, Velcade) and Bcl-2 antisense (Genasense) for the treatment of both newly diagnosed and refractory MCL patients. Bortezomib is a reversible proteasome inhibitor. Proteasome inhibition can lead to cell-cycle dysregulation, resulting in apoptosis. Initial results from a small pilot trial demonstrated that multiply treated MCL patients showed evidence of some clinical response.[24] Bcl-2 antisense inhibits Bcl-2 gene expression by hybridization arrest, followed by cleavage of the m-RNA by RNAase-H. In vitro studies have demonstrated synergistic antitumor activity when Bcl-2 antisense is used in combination with standard chemotherapy. The agent is currently being evaluated in a phase II trial, alone or in combination with R-CHOP in patients with newly diagnosed, refrac- tory, or relapsed MCL. Additional novel agents with activity in MCL are needed. Conclusions
This article presents a balanced review of the literature on MCL. Because standard therapies for MCL are not curative, clinical trials of novel therapies, immunotherapies used in combinations, and high-dose chemotherapy with autologous or allogeneic stem cell transplant should be considered for all patients with newly diagnosed or recurrent MCL.


The author(s) have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.


1. Hiddemann W, Unterhalt M, Herrmann R, et al: Mantle-cell lymphomas have more widespread disease and slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 16:1922-1930, 1998.
2. Samaha H, Dumontet C, Ketterer N, et al: Mantle cell lymphoma: A retrospective study of 121 cases. Leukemia 12:1281-1287, 1998. 3. Zucca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995.
4. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995.
5. Ruskone-Formestraux A, Delmer A, Lavergne A, et al: Multiple lymphomatous polyposis of the gastrointestinal tract: A prospective clinicopathologic study of 31 cases. Gastroenterology 112:7-16, 1997.
6. Oinonen R, Franssila K, Teerenhovi L, et al: Mantle cell lymphoma: Clinical features, treatment, and prognosis of 94 patients. Eur J Cancer 34:329-336, 1998.
7. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve prognosis. Hematol Oncol 7:365-380, 1989.
8. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249-256, 1995.
9. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997.
10. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998.
11. Samaha H, Dumontet C, Ketterer N, et al: Mantle cell lymphoma: A retrospective study of 121 cases. Leukemia 12:1281-1287, 1998.
12. Weisenburger DD, Vose JM, Greiner TC, et al: Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 64:190-196, 2000.
13. Romaguera JC, Dang N: Mantle cell lymphoma (MCL)—High rates of complete remission (CR) and prolonged failure-free survival (FFS) with rituxan-hyperCVAD without stem cell transplantation (abstract). Blood 98:3030a, 2001.
14. Vose JM, Bierman PJ, Weisenburger DD, et al: Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 6:640-645, 2000.
15. Geisler CH, Pedersen LB, Andersen N, et al: Mantle cell lymphoma (MCL): Increased clinical and molecular response rates adding ara-C and rituximab to DHOP + BEAM and autologous stem cell transplantation. Results of the 1st and 2nd Nordic MCL protocols (abstract). Blood 100:2534a, 2002.
16. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002.
17. Vose JM, Bierman PJ, Lynch JC, et al: Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for relapsed non-Hodgkin's lymphoma (NHL): Synergistic results with no added toxicity (abstract). Proc Am Soc Clin Oncol 20:19a, 2001.
18. Nademanee A, Molina A, Forman S, et al: A phase I/II trial of high-dose radioimmunotherapy (RIT) with zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplantation (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's Lymphoma (abstract). Blood 100:679a, 2002.
19. Khouri IF, Lee MS, Romaguera J, et al: Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10:1293-1299, 1999.
20. Kroger N, Hoffknecht M, Kruger W, et al: Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 79:578-580, 2000.
21. Hiddemann W, Dreyling M, Unterhalt M: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 30(1 suppl 2):16-20, 2003.
22. Wilson WH, Sattva N, White T, et al: Idiotype vaccine following EPOCH-rituxan treatment in untreated mantle cell lymphoma (abstract). Blood 100:608a, 2002.
23. Leonard J, Vose J, Timmerman J, et al: Personalized recombinant idiotype vaccination after chemotherapy as initial treatment for mantle cell lymphoma (abstract). Blood 100:4792a, 2002.
24. O'Connor O, Moskowitz C, Wright J, et al: Phase II clinical experience with proteasome inhibitor PS-341 in patients with indolent lymphomas (abstract). Blood 100:3063a, 2002.
Loading comments...
Please Wait 20 seconds or click here to close